Literature DB >> 29027065

Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.

Hasan Altinkaynak1, Meltem Ece Kars2, Piraye Zeynep Kurkcuoglu3, Nagihan Ugurlu2.   

Abstract

PURPOSE: The aim of this study was to evaluate the effect of intravitreal injection of aflibercept (IVA) on blood coagulation tests in neovascular age-related macular degeneration (AMD) patients.
METHODS: Thirty-four patients with neovascular AMD (study group) and 32 healthy individuals (control group) were enrolled. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were measured at different times in patients with neovascular AMD.
RESULTS: The levels of PT and aPTT after IVA were decreased at 1 month after the first injection and 1 month after the second injection compared to the baseline measurement in the study group.
CONCLUSIONS: IVA may cause a decrease in the levels of PT and aPTT at 1 month after the first injection and 1 month after the second injection although these results are not statistically significant in our study.

Entities:  

Keywords:  Activated partial thromboplastin time; Aflibercept; Age-related macular degeneration; Arterial thrombotic events; Prothrombin time

Mesh:

Substances:

Year:  2017        PMID: 29027065     DOI: 10.1007/s10792-017-0741-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  37 in total

1.  Pre-acquisition system assessment of the Sysmex(®) Coagulation System CS-2100i and comparison with end-user verification; a model for the regional introduction of new analysers and methods.

Authors:  Pascal J Molenaar; Anja Leyte
Journal:  Clin Chem Lab Med       Date:  2011-06-10       Impact factor: 3.694

2.  Plasma antiphospholipid antibody levels in age-related macular degeneration.

Authors:  Berna Özkan; Levent V Karabaş; Özgül Altıntaş; Gülden Sönmez Tamer; Nurşen Yüksel; Yusuf Çağlar
Journal:  Can J Ophthalmol       Date:  2012-05-12       Impact factor: 1.882

3.  Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study.

Authors:  Chao-Chien Hu; Jau-Der Ho; Herng-Ching Lin
Journal:  Stroke       Date:  2010-02-11       Impact factor: 7.914

4.  Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study.

Authors:  B Muñoz; S K West; G S Rubin; O D Schein; H A Quigley; S B Bressler; K Bandeen-Roche
Journal:  Arch Ophthalmol       Date:  2000-06

5.  Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.

Authors:  Cristina Legnani; Silvia Mattarozzi; Michela Cini; Benilde Cosmi; Elisabetta Favaretto; Gualtiero Palareti
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

6.  Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.

Authors:  Izumi Yoshida; Tomoaki Shiba; Hikari Taniguchi; Mao Takahashi; Takeyoshi Murano; Nobuyuki Hiruta; Yuichi Hori; Hdieaki Bujo; Takatoshi Maeno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-17       Impact factor: 3.117

7.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

8.  Retinal artery occlusion following intravitreal anti-VEGF therapy.

Authors:  Therese von Hanno; Bettina Kinge; Kristian Fossen
Journal:  Acta Ophthalmol       Date:  2009-04-08       Impact factor: 3.761

Review 9.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

Review 10.  Update on angiogenesis inhibitors.

Authors:  Anaadriana Zakarija; Gerald Soff
Journal:  Curr Opin Oncol       Date:  2005-11       Impact factor: 3.645

View more
  2 in total

1.  Changes of plasma nitric oxide, endothelin-1, and blood coagulation following intravitreal conbercept.

Authors:  Quan-Yong Yi; Li-Shuang Chen; Yu Shen; Yan-Hong Liao; Yan-Yan Wang; Jie Yang; Yuanhui Jin; Lingyun Cheng
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

2.  Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept.

Authors:  Michał Wiciński; Małgorzata Seredyka-Burduk; Sławomir Liberski; Daria Marczak; Magdalena Pol; Bartosz Malinowski; Katarzyna Pawlak-Osińska; Bartlomiej J Kaluzny
Journal:  Life (Basel)       Date:  2021-05-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.